<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02204241</url>
  </required_header>
  <id_info>
    <org_study_id>IST-CAR-601</org_study_id>
    <nct_id>NCT02204241</nct_id>
  </id_info>
  <brief_title>Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients</brief_title>
  <acronym>CCD</acronym>
  <official_title>A Multicenter, Open Label Phase I/II Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Myeloma Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione EMN Italy Onlus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Myeloma Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a phase I/II multicenter study designed to assess the safety and the&#xD;
      efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM)&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment schedule for 9 cycles of induction:&#xD;
&#xD;
      Phase I:&#xD;
&#xD;
      In the phase I portion of the study, the following dose levels of carfilzomib will be studied&#xD;
      with fixed doses of dexamethasone and cyclophosphamide to define the maximum tolerated dose&#xD;
      (MTD):&#xD;
&#xD;
      Level-1:&#xD;
&#xD;
        1. Carfilzomib given 20 mg/m2 IV once daily on days 1-2 of Cycle 1 only followed by 36&#xD;
           mg/m2 on days 8-9, 15-16, of Cycle 1, then for all subsequent doses 36 mg/m2 IV once&#xD;
           daily on days 1-2, 8-9, 15-16.&#xD;
&#xD;
        2. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15&#xD;
&#xD;
        3. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9, 15-16, 22-23&#xD;
&#xD;
      Level 0:&#xD;
&#xD;
        1. Carfilzomib given 20 mg/m2 IV once daily on days 1-2 of Cycle 1 only followed by 45&#xD;
           mg/m2 on days 8-9, 15-16, of Cycle 1, then for all subsequent doses 45 mg/m2 IV once&#xD;
           daily on days 1-2, 8-9, 15-16.&#xD;
&#xD;
        2. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15&#xD;
&#xD;
        3. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9, 15-16, 22-23&#xD;
&#xD;
      Level +1:&#xD;
&#xD;
        1. Carfilzomib given 20 mg/m2 IV once daily on days 1-2 of Cycle 1 only followed by 56&#xD;
           mg/m2 on days 8-9, 15-16, of Cycle 1, then for all subsequent doses 56 mg/m2 IV once&#xD;
           daily on days 1-2, 8-9, 15-16.&#xD;
&#xD;
        2. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15&#xD;
&#xD;
        3. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9, 15-16, 22-23&#xD;
&#xD;
      Level +2:&#xD;
&#xD;
        1. Carfilzomib given 20 mg/m2 IV once daily on days 1-2 of Cycle 1 only followed by 36&#xD;
           mg/m2 on days 8-9, 15-16, of Cycle 1, then for all subsequent doses 70 mg/m2 IV once&#xD;
           daily on days 1-2, 8-9, 15-16.&#xD;
&#xD;
        2. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15&#xD;
&#xD;
        3. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days&#xD;
           1-2, 8-9, 15-16, 22-23&#xD;
&#xD;
      Patient will be observed at the end of the second cycle of therapy for the assessment of side&#xD;
      effects and observation of DLTs. Dose escalation will proceed as follows:&#xD;
&#xD;
        -  3 patients will be entered at dose level 0&#xD;
&#xD;
        -  If 0/3 patients experience DLT, dose escalation will continue&#xD;
&#xD;
        -  If 1/3 patients experience DLT, 3 additional patients will be added to this cohort (max&#xD;
           6)&#xD;
&#xD;
        -  If no further patients experience DLT (1/6) dose escalation will continue&#xD;
&#xD;
        -  If 2/6 patients experience DLT, the MTD will have been exceeded and the MTD will be the&#xD;
           previous dose at which &lt;2/6 experienced DLT&#xD;
&#xD;
        -  If 2/3 patients experience a DLT at any given dose, the MTD will have been exceeded and&#xD;
           the MTD will be the preceding dose at which &lt; 2/6 (or 1/3) patients experienced a DLT.&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
      The dose used to treat patients in the phase II will be the MTD defined in the phase I of the&#xD;
      study.&#xD;
&#xD;
      Treatment schedule for maintenance until progression or intolerance:&#xD;
&#xD;
      Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>1 year</time_frame>
    <description>Non-hematologic:&#xD;
Grade 2 neuropathy with pain&#xD;
any Grade 3 tox. (excluding nausea, vomiting, diarrhea)&#xD;
Grade 3 nausea, vomiting, or diarrhea despite maximal antiemetic/antidiarrheal therapy&#xD;
Grade 4 fatigue lasting for ≥ 7 days&#xD;
Any non-hematologic tox. requiring a dose reduction within Cycle 1&#xD;
Inability to receive Day 1 dose of Cycle 2 due to drug related tox. persisting from Cycle 1 or drug related tox. newly encountered on Day 1 of Cycle 2.&#xD;
Hematologic:&#xD;
Grade 4 neutropenia (ANC &lt; 0.5 x 109/L) lasting for ≥ 7 days&#xD;
Febrile neutropenia (ANC &lt; 1.0 x 109/L with a fever ≥ 38.3ºC)&#xD;
Grade 4 thrombocytopenia (platelets &lt; 25.0 x 109/L) lasting ≥ 7 days despite dose delay&#xD;
Grade 3-4 thrombocytopenia associated with bleeding&#xD;
Any hematologic tox. requiring a dose reduction within Cycle 1&#xD;
Inability to receive Day 1 dose of Cycle 2 due to drug related tox. persisting from Cycle 1 or drug related tox. newly encountered on Day 1 of Cycle 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the time to progression (TTP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next therapy (TTNT)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the time to next therapy (TTNT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses</measure>
    <time_frame>3 years</time_frame>
    <description>Determine whether responses obtained with CCyd treatment are associated with a prolongation of PFS, in comparison with non-responding patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response and survival</measure>
    <time_frame>3 years</time_frame>
    <description>Determine whether tumor response and outcome may change in subgroups with different prognosis according to current prognostic factors (β2-microglobulin, C-reactive protein (CRP), FISH, gene expression profile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the benefit on PFS and OS of maintenance with carfilzomib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>1 years</time_frame>
    <description>The toxicity is defined as the first occurrence of a grade 4 hematologic drug-related toxicity (grade 4 neutropenia must last longer than 3 days and grade 4 thrombocytopenia must last longer than 7 days in order to be considered a toxicity) excluding anemia. Assessment of adverse events will be performed at the end of third cycle according to the National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE version 4.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CCyd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment schedule for 9 cycles of induction:&#xD;
Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.&#xD;
Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).&#xD;
Treatment schedule for maintenance until progression or intolerance:&#xD;
Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <arm_group_label>CCyd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>CCyd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>CCyd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is of a legally consenting age as defined by local regulations.&#xD;
&#xD;
          -  Patient is age ≥ 65 year of age or who are ineligible for autologous stem cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Patient is, in the investigator(s) opinion, willing and able to comply with the&#xD;
             protocol requirements.&#xD;
&#xD;
          -  Patient has given voluntary written informed consent before performance of any&#xD;
             study-related procedure not part of normal medical care, with the understanding that&#xD;
             consent may be withdrawn by the patient at any time without prejudice to their future&#xD;
             medical care.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within the 7&#xD;
             days prior to study drug administration and a negative urine pregnancy test within the&#xD;
             3 days prior to the first study drug administration.&#xD;
&#xD;
          -  Women of childbearing potential and male subjects who are sexullay active with WOCBP&#xD;
             must agree to use 2 highly effective methods of contraception during the study and for&#xD;
             30 days following the last dose of study treatment including a male condom.&#xD;
&#xD;
          -  Patient is a newly diagnosed MM patient.&#xD;
&#xD;
          -  Patient has measurable disease, defined as follows: any quantifiable serum monoclonal&#xD;
             protein value (generally, but not necessarily, ≥ 0.5 g/dL of M-protein) and, where&#xD;
             applicable, urine light-chain excretion of &gt;200 mg/24 hours. For patients with oligo&#xD;
             or non-secretory MM, it is required that they have measurable plasmacytoma &gt; 2 cm as&#xD;
             determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or an&#xD;
             abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that less than 10% of&#xD;
             patients admitted to this study will be oligo- or non-secretory MM with free light&#xD;
             chains only in order to maximize interpretation of benefit results.&#xD;
&#xD;
          -  Patient has a Karnofsky performance status ≥60%.&#xD;
&#xD;
          -  Patient has a life-expectancy &gt;3 months.&#xD;
&#xD;
          -  Patient has the following laboratory values within 14 days before Baseline (day 1 of&#xD;
             the Cycle 1, before study drug administration):&#xD;
&#xD;
               -  Platelet count ≥50 x 109/L (≥30 x 109 /L if myeloma involvement in the bone&#xD;
                  marrow is &gt; 50%) within 14 days prior to drug administration.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1 x 109/L without the use of growth factors.&#xD;
&#xD;
               -  Corrected serum calcium ≤14 mg/dL (3.5 mmol/L)&#xD;
&#xD;
               -  Alanine transaminase (ALT): ≤ 3 x the ULN.&#xD;
&#xD;
               -  Total bilirubin: ≤ 2 x the ULN.&#xD;
&#xD;
               -  Calculated or measured creatinine clearance: ≥ 15 mL/minute&#xD;
&#xD;
               -  LVEF ≥40%. 2D transthoracic ECHO is the preferred method of evaluation.&#xD;
                  Multigated Acquisition Scan is acceptable if ECHO is not available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with non-secretory MM, unless serum free light chains are present and the&#xD;
             ratio is abnormal.&#xD;
&#xD;
          -  Women who are pregnant and/or breast feeding.&#xD;
&#xD;
          -  Patient has active infectious hepatitis type B or C or HIV.&#xD;
&#xD;
          -  Pulmonary Hypertension.&#xD;
&#xD;
          -  QTc Interval ≥ 450 msec.&#xD;
&#xD;
          -  Uncontrolled Atrial Fibrillation/Flutter.&#xD;
&#xD;
          -  History of Torsade de pointe, Ventricular Tachycardia, Ventricular Fibrillation.&#xD;
&#xD;
          -  Uncontrolled Infection.&#xD;
&#xD;
          -  Patients with myocardial infarction or unstable angina ≤ 4 months or other clinically&#xD;
             significant heart disease (e.g., CHF NY Heart Association class III or IV,&#xD;
             uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
             compliance with an antihypertensive regimen).&#xD;
&#xD;
          -  Patient with peripheral neuropathy &gt; CTCAE grade 2.&#xD;
&#xD;
          -  Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize&#xD;
             carfilzomib).&#xD;
&#xD;
          -  Contraindication to any of the required concomitant drugs or supportive treatments,&#xD;
             including hypersensitivity to all anticoagulation and antiplatelet options, antiviral&#xD;
             drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.&#xD;
&#xD;
          -  Subjects with pleural effusions requiring thoracentesis or ascites requiring&#xD;
             paracentesis within 14 days prior to baseline.&#xD;
&#xD;
          -  Patient has any other clinically significant illness that would, in the investigator's&#xD;
             opinion, increase the patient's risk for toxicity.&#xD;
&#xD;
          -  Patients with a prior malignancy within the last 5 years (except for basal or squamous&#xD;
             cell carcinoma, or in situ cancer of the cervix or breast, or localized prostate&#xD;
             cancer of Gleason score &lt;7 with a stable PSA).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione EMN Italy Onlus</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2014</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>CCyd</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

